Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$4.19
-0.17 (-3.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $220.9M · quality 35.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
6/100
F
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-24.8%
↓Gross Margin
49.6%
↑Debt/Equity
0.90
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-14.1%
FCF CAGR
—
FCF margin
9.7%
FCF / Net income
-0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.27B · net income $-288.6M · FCF $220.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.27B | $2.27B | $2.65B | $2.36B | $3.59B |
| Net Income | $-288.6M | $-288.6M | $-965.5M | $-661.1M | $-1.22B |
| EBITDA | $-29.2M | $-29.2M | $-682.7M | $-319.8M | $-1.11B |
| EPS | -0.27 | -0.27 | -0.91 | -0.61 | -0.86 |
| Gross Margin | 49.6% | 49.6% | 42.1% | 46.3% | 26.7% |
| Operating Margin | -6.2% | -6.2% | -14.0% | -14.5% | -39.4% |
| Net Margin | -12.7% | -12.7% | -36.5% | -28.0% | -34.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.90 | 0.90 | 1.14 | 0.60 | 1.11 |
| Current Ratio | 0.76 | 0.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $220.9M | $220.9M | $-273.2M | $224.5M | $-1.13B |
| Returns | |||||
| ROE | -24.8% | -24.8% | -69.8% | -26.8% | -38.6% |
| Valuation | |||||
| P/B | 3.82 | 3.82 | 3.22 | 2.29 | 3.68 |
| Growth & Yield | |||||
| Revenue Growth | -14.1% | -14.1% | 12.0% | -34.1% | — |
| EPS Growth | 70.0% | 70.0% | -48.5% | 29.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.91 → -0.27
Residual
-5.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.